This episode examines pharmacologic strategies used to treat protozoal and helminth infections. Drawing from Murray’s Chapter 71, it explores how antiparasitic therapy must account for organism complexity, life cycle stage, and host toxicity.

Unlike bacteria, parasites are eukaryotic and often multicellular. This limits therapeutic selectivity and requires targeting unique metabolic pathways or structural vulnerabilities.

Major drug classes include:

* Antimalarials (e.g., chloroquine, artemisinin-based therapies)

* Antiprotozoals (e.g., metronidazole, nitazoxanide)

* Antihelminthics (e.g., albendazole, mebendazole, ivermectin, praziquantel)

Drug choice depends on:

* Parasite species

* Life cycle stage

* Tissue location

* Host immune status

Resistance patterns and geographic variation influence therapy selection, particularly in malaria.

Conceptually, antiparasitic therapy demands ecological awareness - drugs must intersect precisely with parasite biology without overwhelming host physiology.

Key Takeaways

* Parasites are eukaryotic, limiting drug selectivity

* Treatment depends on life cycle stage

* Albendazole and praziquantel are key antihelminthics

* Artemisinin combinations are central in malaria therapy

* Geographic resistance patterns guide drug choice

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe